Earnings Recaps

Browse reported earnings of the most popular stocks

Nov 13, 2026 Nov 12, 2026 Nov 11, 2026 Nov 10, 2026 Nov 9, 2026 Nov 8, 2026 Nov 7, 2026 Nov 6, 2026 Nov 5, 2026 Nov 4, 2026 Nov 3, 2026 Nov 2, 2026 Nov 1, 2026 Oct 31, 2026 Oct 30, 2026 Oct 29, 2026 Oct 28, 2026 Oct 27, 2026 Oct 26, 2026 Oct 25, 2026 Oct 24, 2026 Oct 23, 2026 Oct 22, 2026 Oct 21, 2026 Oct 20, 2026 Oct 19, 2026 Oct 18, 2026 Oct 17, 2026 Oct 16, 2026 Oct 15, 2026 Oct 14, 2026 Oct 13, 2026 Oct 11, 2026 Oct 10, 2026 Oct 9, 2026 Oct 8, 2026 Oct 7, 2026 Oct 3, 2026 Oct 2, 2026 Oct 1, 2026 Sep 30, 2026 Sep 29, 2026 Sep 27, 2026 Sep 26, 2026 Sep 25, 2026 Sep 24, 2026 Sep 23, 2026 Sep 19, 2026 Sep 18, 2026 Sep 17, 2026 Sep 16, 2026 Sep 14, 2026 Sep 13, 2026 Sep 12, 2026 Sep 11, 2026 Sep 10, 2026 Sep 9, 2026 Sep 8, 2026 Sep 5, 2026 Sep 4, 2026 Sep 3, 2026 Sep 2, 2026 Sep 1, 2026 Aug 31, 2026 Aug 30, 2026 Aug 29, 2026 Aug 28, 2026 Aug 27, 2026 Aug 26, 2026 Aug 25, 2026 Aug 23, 2026 Aug 22, 2026 Aug 21, 2026 Aug 20, 2026 Aug 19, 2026 Aug 18, 2026 Aug 17, 2026 Aug 16, 2026 Aug 15, 2026 Aug 14, 2026 Aug 13, 2026 Aug 12, 2026 Aug 11, 2026 Aug 10, 2026 Aug 9, 2026 Aug 8, 2026 Aug 7, 2026 Aug 6, 2026 Aug 5, 2026 Aug 4, 2026 Aug 3, 2026 Aug 2, 2026 Aug 1, 2026 Jul 31, 2026 Jul 30, 2026 Jul 29, 2026 Jul 28, 2026 Jul 27, 2026 Jul 26, 2026 Jul 25, 2026 Jul 24, 2026 Jul 23, 2026 Jul 22, 2026 Jul 21, 2026 Jul 20, 2026 Jul 19, 2026 Jul 18, 2026 Jul 17, 2026 Jul 16, 2026 Jul 12, 2026 Jul 11, 2026 Jul 10, 2026 Jul 9, 2026 Jul 3, 2026 Jul 2, 2026 Jul 1, 2026 Jun 30, 2026 Jun 28, 2026 Jun 27, 2026 Jun 26, 2026 Jun 25, 2026 Jun 24, 2026 Jun 20, 2026 Jun 19, 2026 Jun 18, 2026 Jun 17, 2026 Jun 15, 2026 Jun 14, 2026 Jun 13, 2026 Jun 12, 2026 Jun 11, 2026 Jun 10, 2026 Jun 9, 2026 Jun 6, 2026 Jun 5, 2026 Jun 4, 2026 Jun 3, 2026 Jun 2, 2026 Jun 1, 2026 May 31, 2026 May 30, 2026 May 29, 2026 May 28, 2026 May 27, 2026 May 26, 2026 May 24, 2026 May 23, 2026 May 22, 2026 May 21, 2026 May 20, 2026 May 19, 2026 May 18, 2026 May 17, 2026 May 16, 2026 May 15, 2026 May 14, 2026 May 13, 2026 May 12, 2026 May 11, 2026 May 10, 2026 May 9, 2026 May 8, 2026 May 7, 2026 May 6, 2026 May 5, 2026 May 4, 2026 May 3, 2026 May 2, 2026 May 1, 2026 Apr 30, 2026 Apr 29, 2026 Apr 23, 2026 Apr 22, 2026 Apr 21, 2026 Apr 20, 2026 Apr 18, 2026 Apr 17, 2026 Apr 16, 2026 Apr 15, 2026 Apr 14, 2026 Apr 13, 2026 Apr 10, 2026 Apr 9, 2026 Apr 8, 2026 Apr 7, 2026 Apr 2, 2026 Apr 1, 2026 Mar 31, 2026 Mar 30, 2026 Mar 26, 2026 Mar 25, 2026 Mar 20, 2026 Mar 19, 2026 Mar 18, 2026 Mar 17, 2026 Mar 16, 2026 Mar 13, 2026 Mar 12, 2026 Mar 11, 2026 Mar 9, 2026 Mar 7, 2026 Mar 6, 2026 Mar 5, 2026 Mar 4, 2026 Mar 3, 2026
20 companies Today

Alkane Resources Ltd.

ALK.TO Q1 2027
Reported: 2026-10-26

Alkane shares fell 16.1% after the results, despite production and costs tracking to guidance. The transcript points to a steady quarter rather than a clear catalyst for the selloff; management also reiterated lower grades at some operations and substantial planned investment, but did not identify a guidance cut or specific deterioration.

Key takeaways
  • Q1 production was nearly 41,000 gold-equivalent ounces: 40,000 ounces of gold and just under 400 tonnes of antimony. Management said this keeps Alkane on track for FY27 guidance of 163,000–177,000 gold-equivalent ounces.
  • Consolidated processing was nearly 741,000 tonnes; gold and antimony recoveries were 89.6% and 89.1%, respectively, consistent quarter over quarter. Management said lower grades were offset by higher processing volumes.
  • The three mines generated $102 million in cash flow. Alkane ended the quarter with $459 million in cash, bullion and investments.
  • Planned FY27 growth capital is $160 million–$190 million, with $37 million spent in Q1; broader planned investment, including exploration and Boda-Kaiser work, is $215 million–$255 million.
  • Tomingley produced 21,500 ounces, with AISC of $2,340 per ounce; management attributed the year-over-year cost comparison partly to sustaining-capital timing and maintained full-year site cost guidance.

Allegion plc

ALLE Q3 2026
Reported: 2026-10-26

Allegion’s shares rose 11.0% after earnings, as 7.2% organic revenue growth, margin expansion and a higher full-year outlook showed stronger demand—particularly in the Americas. The outlook still points to difficult conditions in Western Europe and a limited medium-term recovery in Residential.

Key takeaways
  • Q3 revenue was approximately $1.2 billion, up 9.6% year over year; organic revenue grew 7.2%, driven by price and volume.
  • Adjusted operating margin increased 60 basis points to 24.7%. Price and productivity net of inflation and investment added $15.6 million and 50 basis points to the margin rate; acquisitions were a 20-basis-point headwind.
  • Adjusted EPS rose 13% to $2.60. Year-to-date available cash flow was $539.4 million, up 11.2%.
  • Full-year outlook was raised to 9.5%–10.5% reported revenue growth, 5%–6% organic revenue growth and adjusted EPS of $9.05–$9.10.
  • Americas Non-Residential delivered low-double-digit organic growth, with strength expected to continue into 2027. Management said Western Europe remains difficult, while inflation and interest rates make a strong medium-term Residential recovery hard to forecast.

argenx SE

ARGX.BR Q3 2026
Reported: 2026-10-26

Argenx reported $1.7 billion in third-quarter product sales, up 54% year over year, while shares slipped 0.6% after the results. The reaction was roughly flat; the transcript highlights substantial pipeline activity and a December Phase III readout, but provides no new forward financial guidance in the portion provided.

Key takeaways
  • Product net sales were $1.7 billion, up 54% year over year and 13% quarter over quarter.
  • U.S. product sales were $1.5 billion, up 16% quarter over quarter; net pricing was broadly consistent with prior quarters, and gross-to-net deductions were 22%, in line with expectations.
  • Argenx expects the Phase III EMPASSION study readout in MMN in December. The trial compares empasiprubart with IVIg and tests whether it can deliver comparable efficacy with less treatment burden.
  • The company plans to file an sBLA for VYVGART in IMNM by year-end and is moving toward an additional registrational study in dermatomyositis.
  • Management expects five potential launches across the portfolio in 2027 and 10 molecules in clinical development by year-end.

Community

See what investors are trading, holding, and sharing

🌐
All
📈
Stock
📊
ETF
🏦
Mutual Fund
🪙
Crypto
💱
Forex
# Asset Price Community % Type Currency Sector
Loading...